巩固性立体定向消融放疗用于局限性转移性非小细胞肺癌:一项2期随机临床试验
这项单中心随机2期研究纳入29例经诱导化疗后无EGFR/ALK可靶向突变且达部分缓解或疾病稳定的局限性转移性NSCLC患者,比较单纯维持化疗与SAbR后维持化疗。两组毒性相似,SAbR组无野内失败。
要点
- 两组毒性反应相似,SAbR组未观察到野内失败。
- 单纯维持化疗组在原有病灶部位及远处出现进展。
核心结论
- 维持化疗前给予巩固性SAbR似乎有益,在局限性转移性NSCLC患者中较单纯维持化疗使PFS接近三倍,且毒性无差异。
研究设计与样本
- 单中心随机2期研究,纳入29例(女9例、男20例)经诱导化疗后达部分缓解或疾病稳定的局限性转移性NSCLC患者(原发灶加最多5个转移灶,无EGFR可靶向或ALK可靶向突变)。
- SAbR联合维持化疗组14例(中位年龄63.5岁,范围51.0-78.0岁),单纯维持化疗组15例(中位年龄70.0岁,范围51.0-79.0岁)。
主要发现
- 两组毒性反应相似。
- SAbR组无野内失败,总体复发较少;单纯维持化疗组在原有疾病部位及远处出现进展。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patterns-of-failure studies suggest that in metastatic non-small-cell lung cancer (NSCLC) sites of gross disease at presentation are the first to progress when treated with chemotherapy. This knowledge has led to increased adoption of local ablative radiation therapy in patients with stage IV NSCLC, though prospective randomized evidence is limited. OBJECTIVE: To determine if intervening with noninvasive stereotactic ablative radiotherapy (SAbR) prior to maintenance chemotherapy in patients with non-progressive limited metastatic NSCLC after induction therapy led to significant improvements in progression-free survival (PFS). DESIGN, SETTING, AND PARTICIPANTS: This is a single-institution randomized phase 2 study of maintenance chemotherapy alone vs SAbR followed by maintenance chemotherapy for patients with limited metastatic NSCLC (primary plus up to 5 metastatic sites) whose tumors did not possess EGFR-targetable or ALK-targetable mutations but did achieve a partial response or stable disease after induction chemotherapy. INTERVENTIONS: Maintenance chemotherapy or SAbR to all sites of gross disease (including SAbR or hypofractionated radiation to the primary) followed by maintenance chemotherapy. MAIN OUTCOMES AND MEASURES: The primary end point was PFS; secondary end points included toxic effects, local and distant tumor control, patterns of failure, and overall survival. RESULTS: A total of 29 patients (9 women and 20 men) were enrolled; 14 patients (median [range] age, 63.5 [51.0-78.0] years) were allocated to the SAbR-plus-maintenance chemotherapy arm, and 15 patients (median [range] age, 70.0 [51.0-79.0] years) were allocated to the maintenance chemotherapy-alone arm. The trial was stopped to accrual early after an interim analysis found a significant improvement in PFS in the SAbR-plus-maintenance chemotherapy arm of 9.7 months vs 3.5 months in the maintenance chemotherapy-alone arm (P = .01). Toxic effects were similar in both arms. There were no in-field failures with fewer overall recurrences in the SAbR arm while those patients receiving maintenance therapy alone had progression at existing sites of disease and distantly. CONCLUSIONS AND RELEVANCE: Consolidative SAbR prior to maintenance chemotherapy appeared beneficial, nearly tripling PFS in patients with limited metastatic NSCLC compared with maintenance chemotherapy alone, with no difference in toxic effects. The irradiation prevented local failures in original disease, the most likely sites of first recurrence. Furthermore, PFS for patients with limited metastatic disease appeared similar to those patients with a greater metastatic burden, further arguing for the potential benefits of local therapy in limited metastatic settings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02045446.
引用
- Iyengar P, Wardak Z, Gerber DE, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 28973074. doi:10.1001/jamaoncol.2017.3501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。